These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Cutaneous melanoma and the immunotherapy revolution (Review). Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963 [TBL] [Abstract][Full Text] [Related]
31. Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies. Wang R; Chen Y; Xie Y; Ma X; Liu Y Int Immunopharmacol; 2024 May; 132():111989. PubMed ID: 38583243 [TBL] [Abstract][Full Text] [Related]
32. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. Rafei-Shamsabadi D; Lehr S; von Bubnoff D; Meiss F Cancer Immunol Immunother; 2019 Sep; 68(9):1417-1428. PubMed ID: 31422446 [TBL] [Abstract][Full Text] [Related]
33. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460 [TBL] [Abstract][Full Text] [Related]
34. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401 [TBL] [Abstract][Full Text] [Related]
35. Conjunctival Melanoma: Current Treatments and Future Options. Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542 [TBL] [Abstract][Full Text] [Related]
36. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Lau PK; Ascierto PA; McArthur G Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117 [TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! Maio M; Blank C; Necchi A; Di Giacomo AM; Ibrahim R; Lahn M; Fox BA; Bell RB; Tortora G; Eggermont AMM Eur J Cancer; 2021 Jul; 152():155-164. PubMed ID: 34107449 [TBL] [Abstract][Full Text] [Related]
40. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]